QVF · Class II · 21 CFR 866.3982

FDA Product Code QVF: Simple Point-of-care Device To Directly Detect Sars-cov-2 Viral Targets From Clinical Specimens In Near-patient Settings

Rapid point-of-care COVID-19 testing enables immediate clinical decision-making. FDA product code QVF covers simple point-of-care devices for the direct detection of SARS-CoV-2 antigen.

These lateral flow antigen tests provide a visual result within 15 minutes from a nasal or nasopharyngeal swab without laboratory equipment. They are used in clinical settings, schools, workplaces, and at home to identify infectious individuals rapidly.

QVF devices are Class II medical devices, regulated under 21 CFR 866.3982 and reviewed by the FDA Microbiology panel.

Leading manufacturers include Quidel Corporation, Nano-Ditech Corporation and Healgen Scientific, LLC.

9
Total
8
Cleared
202d
Avg days
2023
Since
Stable submission activity - 4 submissions in the last 2 years
Review times improving: avg 169d recently vs 229d historically

FDA 510(k) Cleared Simple Point-of-care Device To Directly Detect Sars-cov-2 Viral Targets From Clinical Specimens In Near-patient Settings Devices (Product Code QVF)

9 devices
1–9 of 9

About Product Code QVF - Regulatory Context

510(k) Submission Activity

9 total 510(k) submissions under product code QVF since 2023, with 8 receiving FDA clearance (average review time: 202 days).

Submission volume has remained relatively stable over the observed period, with 4 submissions in the last 24 months.

FDA 510(k) Review Time - QVF Product Code

Recent submissions under QVF have taken an average of 169 days to reach a decision - down from 229 days historically, suggesting improved FDA processing for this classification.

QVF devices are reviewed by the Microbiology panel. Browse all Microbiology devices →